KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash from Operations (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Cash from Operations for 13 consecutive years, with 81481000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 49.82% to 81481000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 279118000.0, a 53.88% decrease, with the full-year FY2025 number at 279118000.0, down 53.88% from a year prior.
  • Cash from Operations was 81481000.0 for Q4 2025 at Xenon Pharmaceuticals, down from 71752000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 13077000.0 in Q2 2021 to a low of 81481000.0 in Q4 2025.
  • A 5-year average of 39107450.0 and a median of 34870500.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: rose 11.01% in 2022, then tumbled 106.19% in 2025.
  • Xenon Pharmaceuticals' Cash from Operations stood at 20710000.0 in 2021, then tumbled by 70.59% to 35330000.0 in 2022, then fell by 0.2% to 35401000.0 in 2023, then plummeted by 53.63% to 54385000.0 in 2024, then plummeted by 49.82% to 81481000.0 in 2025.
  • Per Business Quant, the three most recent readings for XENE's Cash from Operations are 81481000.0 (Q4 2025), 71752000.0 (Q3 2025), and 64233000.0 (Q2 2025).